Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
Novonesis and Novo Nordisk will explore new solutions to improve metabolic health
02:43am, Monday, 08'th Sep 2025
Novonesis and Novo Nordisk join forces in a new research collaboration to explore solutions that seek to preserve and optimize metabolic health and well-being for people.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options If you purchased or acquired se
NEW YORK, Sept. 06, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28,
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
10:09am, Saturday, 06'th Sep 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options If you purchased or acquired se
NEW YORK, Sept. 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO).
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
07:41am, Saturday, 06'th Sep 2025
NEW YORK , Sept. 6, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2025
Novo Nordisk: Keep It Low So I Can Keep Accumulating (Rating Upgrade)
06:10pm, Friday, 05'th Sep 2025
Novo Nordisk A/S's strong Q2 results, led by Wegovy's explosive growth and robust profitability, reinforce my bullish outlook and justify recent share accumulation. NVO dominates the obesity and diabe
September 30, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against NVO
05:02pm, Friday, 05'th Sep 2025
NEW YORK, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
04:10pm, Friday, 05'th Sep 2025
LOS ANGELES , Sept. 5, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Novo Nordisk A/S
Novo Nordisk Vs Eli Lilly: Novo A Clear Winner
01:10pm, Friday, 05'th Sep 2025
Novo Nordisk stands out as the best pharma stock, outperforming Eli Lilly in key areas. Novo's higher profitability, stronger cash flow, and much lower valuation make it a more attractive investment t
NEW YORK , Sept. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
Bagsværd, Denmark, 5 September 2025 – Novo Nordisk today announced the presentation of 35 abstracts from across its diabetes and obesity portfolio at the upcoming European Association for the Stud
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
Novo Nordisk Is a Strong Buy After the 2025 Pullback
01:36pm, Thursday, 04'th Sep 2025
Novo Nordisk's 2025 correction presents a rare long-term buying opportunity, supported by strong clinical data, resilient financials, and a technical setup signaling a potential rebound.
LOS ANGELES, Sept. 04, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded
